Health Care [ 12/12 ] | Health Care Equipment & Supplies [ 44/74 ]
NASDAQ | Common Stock
AtriCure, Inc. develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally.
The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.
It also provides cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; EPi-Sense Systems, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation; cryoSPHERE probe, which provides temporary pain relief by applying cryothermic energy to targeted intercoastal peripheral nerves in the ribcage; AtriClip System, an implantable device coupled to a single-use disposable applier; and LARIAT System, a suture-based solution for soft-tissue closure.
In addition, the company sells Lumitip dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; Subtle Cannula's to support access for EPi-Sense catheters; and various reusable cardiac surgery instruments.
It markets and sells its products through independent distributors and direct sales personnel.
The company was incorporated in 2000 and is headquartered in Mason, Ohio.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Jul 30, 24 | -0.17 Decreased by -54.55% | -0.17 |
| May 1, 24 | -0.28 Decreased by -21.74% | -0.23 Decreased by -21.74% |
| Feb 15, 24 | -0.21 Decreased by -133.33% | -0.23 Increased by +8.70% |
| Nov 1, 23 | -0.20 Increased by +25.93% | -0.31 Increased by +35.48% |
| Jul 25, 23 | -0.11 Increased by +65.63% | -0.30 Increased by +63.33% |
| May 2, 23 | -0.23 Increased by +30.30% | -0.34 Increased by +32.35% |
| Feb 21, 23 | -0.09 Increased by +70.00% | -0.18 Increased by +50.00% |
| Nov 1, 22 | -0.27 Decreased by -112.80% | -0.25 Decreased by -8.00% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 24 | 115.91 M Increased by +17.93% | -7.85 M Increased by +13.27% | Decreased by -6.78% Increased by +26.46% |
| Jun 30, 24 | 116.27 M Increased by +15.21% | -8.01 M Decreased by -56.47% | Decreased by -6.89% Decreased by -35.81% |
| Mar 31, 24 | 108.85 M Increased by +16.43% | -13.27 M Decreased by -104.89% | Decreased by -12.19% Decreased by -75.99% |
| Dec 31, 23 | 106.54 M Increased by +21.03% | -9.79 M Decreased by -134.75% | Decreased by -9.19% Decreased by -93.95% |
| Sep 30, 23 | 98.29 M Increased by +18.07% | -9.05 M Increased by +26.21% | Decreased by -9.21% Increased by +37.51% |
| Jun 30, 23 | 100.92 M Increased by +19.39% | -5.12 M Increased by +65.51% | Decreased by -5.07% Increased by +71.11% |
| Mar 31, 23 | 93.49 M Increased by +25.37% | -6.48 M Increased by +57.35% | Decreased by -6.93% Increased by +65.98% |
| Dec 31, 22 | 88.03 M Increased by +20.23% | -4.17 M Increased by +69.65% | Decreased by -4.74% Increased by +74.76% |